Examine The Market Position And Future Outlook For Johnson & Johnson
Research and Markets has announced the addition of PharmaVitae 2004: Johnson & Johnson Global & US Analysis to their offering.
(PRWEB) October 25, 2004
Research and Markets (http://www. researchandmarkets. com/reports/c7978 (http://www. researchandmarkets. com/reports/c7978)) has announced the addition of PharmaVitae 2004: Johnson & Johnson Global & US Analysis to their offering.
Introduction
This analysis examines the market position and future outlook for J&J. The profile encompasses global and US specific company strategy, portfolio and pipeline analysis and assessment of financial performance, with US, rest of world and global forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information
Reasons to Purchase
Understand how J&Js mature product portfolio and risk of generic competition will threaten sales growth over the forecast period
Benchmark Johnson & Johnsons performance against key rivals in the ethical pharmaceuticals sector
Learn why J&J must continue to focus on M&A and licensing to generate sales growth over the forecast period
Report Contents:
CHAPTER 1 EXECUTIVE SUMMARY 4
Key findings 4
Current positioning: competitive outlook 2003 5
Future performance: growth drivers and resistors 2004–10 6
Evolution in therapeutic focus: 2003 – 10 7
Key issues facing Johnson & Johnson: 2004 – 10 8
Strategic outlook 9
CHAPTER 2 GLOBAL COMPANY STRATEGY 18
Introduction to Johnson & Johnson 19
Assessment of strategic position 20
Strengths 20
Weaknesses 22
Opportunities 24
Threats 26
Therapeutic foci 28
R&D productivity 31
Development opportunities 32
Organic growth 33
Partnerships/licensing 34
Mergers and acquisitions 35
Geographical expansion 38
Implications of financial position 40
CHAPTER 3 GLOBAL PORTFOLIO AND PIPELINE ANALYSIS 41
Therapy area focus in 2003 42
Business development by therapy area 45
Forecast revenue stream, 2004–10 48
Therapy area forecasts to 2010 48
CNS franchise 52
Marketed products 52
R&D compounds 78
CNS portfolio sales forecasts and forecast revenue growth 80
Oncology franchise 81
Marketed products 81
R&D compounds 88
Oncology portfolio sales forecasts and forecast revenue growth 89
Infectious disease franchise 90
Marketed products 90
R&D compounds 99
Infectious disease portfolio sales forecasts and forecast revenue growth 99
Arthritis, immune and inflammatory disorders (AIID) franchise 100
Marketed products 100
R&D compounds 107
AIID portfolio sales forecasts and forecast revenue growth 109
Gastrointestinal franchise 110
Marketed products 110
R&D compounds 115
Gastrointestinal portfolio sales forecasts and forecast revenue growth 115
WomenÂ’s health franchise 116
Marketed products 116
R&D compounds 122
WomenÂ’s health portfolio sales forecasts and forecast revenue growth 122
Other products 123
Marketed products 124
R&D compounds 129
Other products sales forecasts and forecast revenue growth 130
CHAPTER 4 US STRATEGY, PORTFOLIO AND PIPELINE 131
US Company Strategy 132
US marketing strategy 132
US product sourcing strategy 133
US Portfolio and pipeline analysis 133
US therapy area focus in 2003 133
Forecast US revenue stream, 2004–10 136
CNS portfolio US sales forecasts and forecast revenue growth 139
Oncology portfolio US sales forecasts and forecast revenue growth 141
Arthritis, immune and inflammatory disorders (AIID) portfolio US sales forecasts and forecast revenue growth 142
Infectious disease portfolio US sales forecasts and forecast revenue growth 144
WomenÂ’s health portfolio US sales forecasts and forecast revenue growth 145
Gastrointestinal portfolio US sales forecasts and forecast revenue growth 146
Other products portfolio US sales forecasts and forecast revenue growth 147
CHAPTER 5 CORPORATE DEVELOPMENT 149
Financial position, 2002 - 2003 150
Profitability, 1999-2003 150
Revenue growth 150
Cost structure 152
Profitability 153
Liquidity, 1999–2003 154
2003 performance benchmarking 156
Business model clustering according to 2003 cost ratios 156
2003 growth and investment momentum 157
Key events shaping corporate activity, 1999–2003 159
Merger and acquisition activity 159
Corporate alliances and deals 162
Regulatory affairs 165
Other business development and news 166
CHAPTER 6 APPENDIX: SUPPORTING DATA 168
Methodology for therapy area forecasting 168
For more information visit http://www. researchandmarkets. com/reports/c7978 (http://www. researchandmarkets. com/reports/c7978)
Laura Wood
Senior Manager
Research and Markets
Press@researchandmarkets. com
Fax: +353 1 4100 980
###
